RxDoctor Payments Data

You-Tan Yeh, MD

Internal Medicine · Lodi, CANPI 1952574352

Payments from drug & device makers

$1,428in general payments, 2019–2025

Across 83 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$253
  • GSK$143
  • AstraZeneca$136
  • Johnson & Johnson$129
  • Kowa Pharmaceuticals America, Inc.$123
  • Novo Nordisk$97
  • plus $547 from 13 others

What the payments were for

  • Food & beverage$1,428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,428 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$29,231
Medicare patients
173
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$22,654
EliquisApixaban32$21,065
LinzessLinaclotide13$12,261
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,616
FarxigaDapagliflozin Propanediol11$8,119
Tresiba Flextouch U-100Insulin Degludec13$6,352
Novolog FlexpenInsulin Aspart15$5,734
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,351
Atorvastatin Calcium265$2,732
Gabapentin65$2,261
Albuterol Sulfate HfaAlbuterol Sulfate24$2,107
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,797
Levothyroxine Sodium117$1,614
Amlodipine Besylate167$1,361
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic16$1,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$97$22,65427 claims
PfizerEliquis$70$21,06532 claims
AbbVieLinzess, Synthroid$19$12,98938 claims
GSKTrelegy Ellipta$143$11,61613 claims
AstraZenecaFarxiga$136$8,11911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →